← Back to Search

Other

GLY-200 for Obesity

Verified Trial
Phase 2
Waitlist Available
Research Sponsored by Glyscend, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
You have been diagnosed with Obesity
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, week 1, week 2, week 4, week 6, week 8, week 12, and week 16
Awards & highlights

Summary

This trial will test how well GLY-200 works, how safe it is, and how well participants can tolerate it in people with obesity.

Who is the study for?
This trial is for individuals with obesity who are looking to participate in a study evaluating the effectiveness of a new treatment. Specific eligibility details aren't provided, but typically participants should be adults meeting certain body weight criteria without significant health issues that could interfere with the study.
What is being tested?
The trial is testing GLY-200, which is potentially a new medication for obesity. Participants will either receive GLY-200 or a placebo (a substance with no therapeutic effect) over 16 weeks to compare outcomes.
What are the potential side effects?
While specific side effects are not listed, common side effects in obesity medication trials can include gastrointestinal issues like nausea or constipation, headaches, increased blood pressure, and potential metabolic changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, week 1, week 2, week 4, week 6, week 8, week 12, and week 16
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, week 1, week 2, week 4, week 6, week 8, week 12, and week 16 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Percent change from baseline in weight
Proportion of participants who achieve ≥ 5% body weight reduction
Secondary study objectives
Change and percent change from baseline in weight
Change from baseline in waist circumference
Incidence of adverse events (AEs) and serious adverse events (SAEs) considered by the Investigator to be related to study drug administration
+1 more

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: GLY-200Experimental Treatment1 Intervention
Participants will receive 2.0 g GLY-200 orally twice daily for 16 weeks.
Group II: PlaceboPlacebo Group1 Intervention
Participants will receive placebo (identical in appearance to GLY-200) orally twice daily for 16 weeks.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
GLY-200
2022
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

Glyscend, Inc.Lead Sponsor
1 Previous Clinical Trials
52 Total Patients Enrolled
Mark Fineman, PhDStudy ChairGlyscend, Inc.
1 Previous Clinical Trials
52 Total Patients Enrolled
~16 spots leftby Dec 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top